Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral

Abstract

Successful tumor immunotherapy with peptides requires the induction of cytotoxic T lympho-cytes (CTLs) rather than antibodies. Mice immunized with mannan conjugated to MUC1, a pep-tide found in large amounts in breast cancer, develop CTL responses. In contrast, immunized patients produce high antibodies with poor CTL responses to MUC1. Here, we provide evidence that this “switch” in the immune response is due to the fact that antibodies against the Galα(1,3)Gal epitope, which are normally present in humans but not mice, cross-react with MUC1 peptides. In particular, mice that lack the gene for the epitope (and that produce anti-Gal antibodies) (Cal−/− mice) are like humans in their response to MUC1 immunization in that they develop antibody rather than CTL responses. After we exposed macrophages from Cal−/− mice in vitro to MUC1, in the absence of Gal antibody, and adoptively transferred them into the mice, Cal−/− mice produced a predominantly CTL response. The findings are of relevance for im-munotherapy studies in humans and emphasize the differences seen in preclinical testing in ro-dents before clinical trials.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Singer, A., Time and truth for cancer vaccines—a new generation. J. Natl. Cancer Inst. 86, 330–330 (1994).

    Article  Google Scholar 

  2. Kawakami, Y. et al. Cloning of the gene coding for a shared human-melanoma anti-gen recognized by autologous T-cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515–3519 (1994).

    Article  CAS  Google Scholar 

  3. Disis, M.L., Smith, J.W., Murphy, A.E., Chen, W., & Cheever, M.A. In vitro generation of human CTL specific for peptides derived from the Her-2/neu protooncogene pro-tein. Cancer Res. 54, 1071–1076 (1994).

    CAS  PubMed  Google Scholar 

  4. Theobald, M., Biggs, J., Dittmer, D., Levine, A.J. & Sherman, L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92, 11993–11997 (1995).

    Article  CAS  Google Scholar 

  5. Schendel, D.J. & Gansbacher, B. Tumor specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: Modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res. 53, 4020–4025 (1993).

    CAS  PubMed  Google Scholar 

  6. Apostolopoulos, V., McKenzie, I.F.C. & Pietersz, G.A. Breast cancer immunother-apy—Current status and future prospects. Immunol. Cell Biol. 74, 457–464 (1996).

    Article  CAS  Google Scholar 

  7. Apostolopoulos, V., Xing, P.X. & McKenzie, I.F.C. Murine immune response to cells transfected with human MUC1: Immunization with cellular and synthetic antigens. Cancer Res. 54, 5186–5193 (1994).

    CAS  PubMed  Google Scholar 

  8. Apostolopoulos, V., Pietersz, G.A. & McKenzie, I.F.C. Cell-mediated immune re-sponses to MUC1 fusion protein coupled to mannan. Vaccine 14, 930–938 (1996).

    Article  CAS  Google Scholar 

  9. Apostolopoulos, V., Pietersz, G.A., Loveland, B.E., Sandrin, M.S. & McKenzie, I.F.C. Oxidative/reductive conjugation of mannan to antigen selects for T, or T2 immune responses. Proc. Natl. Acad. Sci. USA 92, 10128–10132 (1995).

    Article  CAS  Google Scholar 

  10. Karanikas, V. et al. Antibody and T cell responses of patients with adenocarcinoma im-munized with mannan-MUCI fusion protein. J. Clin. Invest. 100, 2738–2792 (1997).

    Article  Google Scholar 

  11. Vaughan, H.A. et al. Recognition of an octapeptide sequence by multiple Galα(1,3)Gal-binding proteins. Xenotransplantation 3, 18–23 (1996).

    Article  Google Scholar 

  12. Sandrin, M.S., Vaughan, H.A., Xing, P.X. & McKenzie, I.F.C. Natural human anti-Galα(1,3)Gal antibodies react with human mucin peptides. Glycoconj. J. 14, 97–105 (1997).

    Article  CAS  Google Scholar 

  13. Sandrin, M.S., Vaughan, H.A., Dabkowski, P.L. & McKenzie, I.F.C. Anti-pig antibodies in human serum predominantly with Galα(1,3)Gal epitopes. Proc. Natl. Acad. Sci. USA 90, 11391–11395 (1995).

    Article  Google Scholar 

  14. Vaughan, H.A., Loveland, B.E. & Sandrin, M.S. Galα(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognised by naturally occurring cytotoxic anti-bodies. Transplantation 58, 879–884 (1994).

    Article  CAS  Google Scholar 

  15. McKenzie, I.F.C. et al. Distribution of the major xenoantigens (Galα(1,3)Gal) for pig to human xenografts. Transplant Immunol. 2, 81–86 (1994).

    Article  CAS  Google Scholar 

  16. Galili, U. & La Temple, C. Natural anti-Gal antibody as a universal augmentor of au-tologous tumor vaccine immunogenicity. Immunol. Today 18, 281–285 (1997).

    Article  CAS  Google Scholar 

  17. Celis, E., Abraham, K.G. & Miller, R.W. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 7, 563–568 (1987).

    Article  CAS  Google Scholar 

  18. Amigorena, S. et al. Cytoplasmic domain heterogeneity and functions of IgG Fc re-ceptors in B lymphocytes. Science 256,1801 1812 (1992).

    Article  CAS  Google Scholar 

  19. Bouige, P., Iscaki, S., Cosson, A. & Pillot, J. Molecular analysis of the modulatory fac-tors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. Immunol. Med. Microbiol. 13, 71–79 (1996).

    Article  CAS  Google Scholar 

  20. Heijnen, I.A. et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97, 331–338 (1996).

    Article  CAS  Google Scholar 

  21. Molina, H. et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93, 3357–3361 (1996).

    Article  CAS  Google Scholar 

  22. Lefkovits, I. & Waldmann, H. Limiting dilution analysis of the cells of the immune sys-tem. I. The clonal basis of the immune response. Immunol. Today 5, 265–272 (1984).

    Article  CAS  Google Scholar 

  23. Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J. Immunol. 126, 1614–1619 (1981).

    CAS  Google Scholar 

  24. Fazekas de St. Groth, S. The evaluation of limiting dilution assays [review]. J. Immunol. Methods 49, R11R23 (1982).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Apostolopoulos, V., Osinski, C. & Mckenzie, I. MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 4, 315–320 (1998). https://doi.org/10.1038/nm0398-315

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0398-315

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing